Axoltis Pharma
Latest round
- Series A
Last raised
- Nov 2025
Total raised
- $6.3M
Investors
- 4
About Axoltis Pharma
Axoltis Pharma is a biotechnology company that concentrates on creating therapeutic solutions for degenerative and traumatic neurological conditions.000 mn.Axoltis specializes in developing innovative therapeutics aimed at addressing significant challenges in the treatment of degenerative and traumatic neurological disorders. The company’s flagship product, NX210c, is an advanced therapeutic peptide designed to enhance recovery and improve the functionality and quality of life for patients suffering from these conditions. NX210c targets high unmet medical needs in the neurological space, specifically focusing on conditions that require immediate and effective intervention. The primary end users of Axoltis’s products are healthcare providers who treat patients with these disorders, particularly in regions with limited therapeutic options.Axoltis's revenue model is centered around the commercialization of its novel therapeutic product, NX210c, through strategic partnerships and collaborations with healthcare providers and institutions. Revenue is generated primarily from direct sales to hospitals and clinics, where the product is prescribed to patients with specific neurological disorders. Pricing structures are designed to reflect the value offered by NX210c in terms of improved patient outcomes, although specific pricing details are not disclosed. The company aims to expand its presence in various global markets, although specific regions targeted for expansion have not been detailed.
Who invested in Axoltis Pharma
4 investors across 4 rounds
See all investors in Axoltis Pharma
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about Axoltis Pharma
Who invested in Axoltis Pharma?
Axoltis Pharma has 4 investors on record across 4 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Axoltis Pharma raised?
Axoltis Pharma has raised 4 venture rounds. Sign up free to see how much each round raised and the total.
When did Axoltis Pharma last raise money?
Axoltis Pharma's most recent round on record is a Series A, in Nov 2025.
What does Axoltis Pharma do?
Axoltis Pharma is a biotechnology company that concentrates on creating therapeutic solutions for degenerative and traumatic neurological conditions.
Where is Axoltis Pharma headquartered?
Axoltis Pharma is headquartered in Clermont-Ferrand, France.
Which VCs invest in companies like Axoltis Pharma?
Among active investors with capital left to deploy, Index Ventures, Forbion, European Investment Bank and Highland Europe back pharmaceuticals companies at Axoltis Pharma's stage. Their profiles are linked below.
VCs backing pharmaceuticals startups at Series A
Raising like Axoltis Pharma? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.